Fatal Disseminated Tuberculosis during Treatment with Ruxolitinib Plus Prednisolone in a Patient with Primary Myelofibrosis: A Case Report and Review of the Literature-Reference-Cited by-同舟云学术

Fatal Disseminated Tuberculosis during Treatment with Ruxolitinib Plus Prednisolone in a Patient with Primary Myelofibrosis: A Case Report and Review of the Literature

Published:2018-05-01 Issue:9 Volume:57 Page:1297-1300
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Tsukamoto Yasuhiro¹²,Kiyasu Junichi¹³,Tsuda Mariko¹²,Ikeda Motohiko¹,Shiratsuchi Motoaki²,Ogawa Yoshihiro²,Yufu Yuji¹

Affiliation:

1. Department of Hematology, Iizuka Hospital, Japan

2. Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Japan

3. Department of Clinical Research Institute, National Kyushu Cancer Center, National Hospital Organization, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/57/9/57_9165-17/_pdf

Reference23 articles.

1. 1. Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol 29: 573-582, 2011.

2. 2. Vannucchi AM, Kantarjian HM, Kiladjian JJ, et al. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica 100: 1139-1145, 2015.

3. 3. Heine A, Brossart P, Wolf D. Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? Blood 122: 3843-3844, 2013.

4. 4. Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 29: 392-397, 2011.

5. 5. Yang JY, Han M, Koh Y, et al. Effects of corticosteroids on critically ill pulmonary tuberculosis patients with acute respiratory failure: a propensity analysis of mortality. Clin Infect Dis 63: 1449-1455, 2016.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Research Progress on Hematogenous Disseminated Tuberculosis;Advances in Clinical Medicine;2024

2. Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis;Haematologica;2023-03-02

3. Recent progress of JAK inhibitors for hematological disorders;Immunological Medicine;2022-10-28

4. Ruxolitinib inhibits cytokine production by human lung macrophages without impairing phagocytic ability;Frontiers in Pharmacology;2022-08-19

5. Fatal Disseminated Tuberculosis and Concurrent Disseminated Cryptococcosis in a Ruxolitinib-treated Patient with Primary Myelofibrosis: A Case Report and Literature Review;Internal Medicine;2022